New semaglutide for alcohol use disorder trial shows big drops in drinking
Strongly significant reductions in drinking across measures. From the abstract: “Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-1 receptor agonists as a potential novel treatment target for alcohol use disorder.”
Always a challenge with such big placebo effects in alcohol trials, and this trial provided real-human CBT to the placebo and semaglutide groups.
Congratulations to Mette Klausen, Anders Fink-Jensen and the rest of the illustrious team! This is a very important paper.